Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Innate Pharma Sa Class A.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.380 Hello and welcome to the full year 2024 financial 00:00:05.380 -- 00:00:09.887 results and business update. All lines have been placed on mute to prevent any background 00:00:09.887 -- 00:00:14.515 noise. After the speaker's remarks, there will be a question and answer session. 00:00:14.515 -- 00:00:18.882 If you would like to ask a question, please press star 1 on your telephone keypad. 00:00:18.882 -- 00:00:23.370 I would now like to turn the conference over to Henry Wheeler, Vice President, Investor 00:00:23.370 -- 00:00:27.593 Relations and Communications. You may begin. 00:00:28.837 -- 00:00:31.580 Thank you. Good morning, good afternoon, and welcome, everyone. 00:00:31.580 -- 00:00:36.825 This morning, Innate issued a press release for our full year 2024 business update 00:00:36.825 -- 00:00:41.429 and financial results. We look forward to highlighting the progress made during the year 00:00:41.429 -- 00:00:45.393 to date, as well as addressing future goals and milestones. 00:00:45.393 -- 00:00:50.438 The press release and today's presentation are both available on the IR section of our 00:00:50.438 -- 00:00:52.080 website. 00:00:52.080 -- 00:00:57.225 On slide two, before we start, I would like to remind you that we will be making forward-looking 00:00:57.225 -- 00:01:01.316 statements regarding the financial outlook in addition to the regulatory and product 00:01:01.316 -- 00:01:06.402 plan development. These statements are subject to risks and uncertainties that may cause 00:01:06.402 -- 00:01:09.784 actual results to differ from those forecasted. 00:01:09.887 -- 00:01:13.532 On slide three, quickly cover today's agenda. 00:01:13.532 -- 00:01:19.440 After an introduction from Jonathan Dickinson, our CEO, Yanis Morel, COO, ...